What Big Pharma Gets Wrong About 340B

For years, the prescription drug industry has had a stranglehold on the American wallet. We’ve all seen the headlines: skyrocketing insulin prices, life-saving cancer drugs that cost more than a family home, and CEOs taking home eight-figure bonuses while seniors are forced to ration their pills.

Now, Big Pharma is ruthlessly targeting the 340B Drug Discount Program in its quest for bigger profits.

A bi-partisan Congress designed the 340B program around a simple, conservative principle: If drug companies want to access the massive taxpayer-funded markets of Medicaid and Medicare, they must provide a discount to the "safety net" facilities that care for our most vulnerable.

It is not a government subsidy. Not a single taxpayer dollar goes into 340B program discounts. Instead, it is a mandatory price break from some of the wealthiest corporations on the planet. Naturally, Big Pharma hates it. It has spent millions on a sophisticated PR campaign to convince us that the problem with American healthcare isn't the $500 EpiPen—it’s the local hospital trying to keep its doors open.

Critics claim that hospitals are "pocketing the difference" when they receive 340B discounts. This is a deliberate mischaracterization of how a community hospital functions. When a local hospital saves money on drug costs through 340B, that money doesn't go to a yacht in the Mediterranean. It pays for:

• Keeping rural emergency rooms open 24/7.
• Funding mobile clinics that reach veterans in remote areas.
• Providing free screenings and mental health services that would otherwise disappear.

If we "reform" 340B by adding layers of red tape or switching to a "rebate" system controlled by the drug companies, we would effectively hand over the keys of our local healthcare system to the tender mercies of companies like Pfizer and Merck. They want to be the ones who decide which hospitals are "worthy" of a discount. Do we really want a boardroom in New Jersey deciding if a clinic in rural Ohio is "charitable" enough to survive?

The most laughable argument in the Big Pharma playbook is the claim that these discounts hurt "biomedical research and development." This is a scare tactic. The truth is that many of these companies spend more on advertising and stock buybacks than they do on actual R&D.

Furthermore, much of the foundational research for "groundbreaking treatments" is funded by your tax dollars through the National Institutes of Health. To suggest that providing a discount to a community hospital will stop the next cure for cancer is not just wrong—it insults the intelligence of the American taxpayer.

The push for "transparency and accountability" sounds nice in a Washington press release, but in practice, it’s often code for "bureaucratic strangulation." The 340B program is one of the few tools we have left to ensure that healthcare remains local and accessible. Any "reform" that is cheered on by the same pharmaceutical giants that have spent decades lobbying to keep drug prices at record highs will be a disaster for local safety net providers. These companies aren't worried about "safety-net integrity"—they are preoccupied with quarterly earnings reports.